William V. Bobo, MD, MPH

  • 13Articles
  • 48.3KReads
  • 2003–2025Active
  • 76Collaborators
  • 166Citations

About

William V. Bobo, MD, MPH, is affiliated with the Department of Behavioral Sciences and Social Medicine at Florida State University College of Medicine. His publications from 2003 to 2025 focus on clinical topics including schizophrenia and schizoaffective disorders, major depressive disorder, bipolar disorder, addiction, neurology, and stroke. His work covers treatment-resistant depression programs, pharmacological augmentation strategies, metabolic effects of antipsychotics, and comparative effectiveness in bipolar disorder. Bobo has frequently collaborated with authors such as Herbert Y. Meltzer, Richard C. Shelton, and Andrew A. Nierenberg.

Publications

JCP
Developing a Treatment-Resistant Depression Consultation Program, Part II: Assessment
Consensus Statement

Developing a Treatment-Resistant Depression Consultation Program, Part II: Assessment

May 7, 2025

Consensus recommendations about the goals of a consultation for treatment-resistant depression include establishing the primary diagnosis and comorbidities, clarifying symptoms, identifying goals, documenting treatment history, identifying treatment barriers, and...
, , , et al
JCP
Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations
Consensus Statement

Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations

April 28, 2025

Key practical considerations are described, including systems-level and financial issues; equity and access to TRD care for a diverse population; selecting a target population and facilitating referrals; communication between...
, , , et al
JCP
Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment
Original Research

Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment

June 27, 2022

The aim of this study was to develop and validate a categorical definition of “no meaningful benefit” from antidepressant treatment by equating percent change in scores on 3 common...
, , , et al
JCP
Original Research

Urine Drug Screens and Youth Mortality

January 11, 2022

Current practices for estimating the risk for mortality in teenage substance users rely heavily on clinical intuition. This study examined whether a positive urine drug screen in youth receiving...
, ,
JCP
Letter to the Editor

BMI and Remission in Depressed Patients Receiving IV Ketamine

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...
, , , et al
JCP
Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
, , , et al
JCP
Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

, , , et al
JCP
Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

, , , et al
JCP
Original Research

A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

July 12, 2011

, , , et al
JCP
Book Review

The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis

December 31, 2008

JCP
Original Research

Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

May 11, 2008

, , , et al
JCP
Original Research

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

February 14, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe